ZYUS Life Sciences Corporation (TSXV: ZYUS) announced preliminary results from its Phase 2a UTOPIA-1 trial evaluating Trichomylin softgel capsules in ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE